Illumina, Inc. has completed the acquisition of SomaLogic, a leader in data-driven proteomics technology, for a total consideration of $350 million in cash paid at closing plus up to $75 million in near-term performance-based milestones and performance-based royalties. The acquisition is aimed at expanding Illumina’s multiomics portfolio, providing customers with access to proteomic insights at scale to drive faster drug discovery and positively impact healthcare.
The acquisition positions Illumina for growth in the expanding proteomics market, leveraging SomaLogic’s technologies and service offerings along with Illumina’s product innovation and global market reach.
The combined capabilities of SomaLogic and Illumina aim to bring high scalability, flexibility, and affordability into protein analysis, providing customers with the ability to generate rich multiomic datasets at scale and adopt tools and workflows that best match their needs.
Illumina will continue to support SomaLogic customers and partnerships, including existing service providers using SomaLogic’s array-based readout.
The financial implications of the transaction will be discussed in Illumina’s upcoming earnings call scheduled for February 5, 2026. The market has reacted to these announcements by moving the company's shares -2.51% to a price of $141.65. If you want to know more, read the company's complete 8-K report here.
